China Biologic Products Performance
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and China Biologic are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days China Biologic Products has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, China Biologic is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
| Quick Ratio | 9.40 | |
| Fifty Two Week Low | 99.13 | |
| Target High Price | 119.00 | |
| Fifty Two Week High | 120.05 | |
| Target Low Price | 77.00 |
China |
China Biologic Relative Risk vs. Return Landscape
If you would invest (100.00) in China Biologic Products on January 20, 2024 and sell it today you would earn a total of 100.00 from holding China Biologic Products or generate -100.0% return on investment over 90 days. China Biologic Products is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than China, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
China Biologic Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for China Biologic's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as China Biologic Products, and traders can use it to determine the average amount a China Biologic's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| CBPO |
Based on monthly moving average China Biologic is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of China Biologic by adding China Biologic to a well-diversified portfolio.
China Biologic Fundamentals Growth
China Stock prices reflect investors' perceptions of the future prospects and financial health of China Biologic, and China Biologic fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on China Stock performance.
| Return On Equity | 9.25 | |||
| Return On Asset | 5.82 | |||
| Profit Margin | 29.04 % | |||
| Operating Margin | 37.26 % | |||
| Current Valuation | 3.56 B | |||
| Shares Outstanding | 38.79 M | |||
| Price To Earning | 31.41 X | |||
| Price To Book | 2.35 X | |||
| Price To Sales | 8.88 X | |||
| Revenue | 524.37 M | |||
| EBITDA | 222.57 M | |||
| Cash And Equivalents | 1.19 B | |||
| Cash Per Share | 30.76 X | |||
| Debt To Equity | 2.30 % | |||
| Book Value Per Share | 51.12 X | |||
| Cash Flow From Operations | 258.48 M | |||
| Earnings Per Share | 3.82 X | |||
| Total Asset | 551.47 M | |||
| Retained Earnings | 834.34 M | |||
| Current Asset | 369.11 M | |||
| Current Liabilities | 71.66 M | |||
Things to note about China Biologic Products performance evaluation
Checking the ongoing alerts about China Biologic for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for China Biologic Products help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| China Biologic is not yet fully synchronised with the market data | |
| China Biologic has some characteristics of a very speculative penny stock | |
| China Biologic has a very high chance of going through financial distress in the upcoming years | |
| About 45.0% of the company shares are held by company insiders |
- Analyzing China Biologic's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether China Biologic's stock is overvalued or undervalued compared to its peers.
- Examining China Biologic's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating China Biologic's management team can have a significant impact on its success or failure. Reviewing the track record and experience of China Biologic's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of China Biologic's stock. These opinions can provide insight into China Biologic's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Other Consideration for investing in China Stock
If you are still planning to invest in China Biologic Products check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the China Biologic's history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |